Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite

Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies

By Carrera S.   Buque A.   Azkona E.   Aresti U.   Calvo B.   Sancho A.   Arruti M.   Nuño M.   Rubio I.   Lobera A.   Lopez C.   Vivanco G.  

Clinical and Translational Oncology, Vol. 16, Iss. 4, 2014-04 ,pp. : 339-350

Springer Publishing Company

Access to resources Recommend Favorite

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

By        

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 2066-2072

Spandidos Publications

Access to resources Recommend Favorite

Biological Characteristics and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Efficacy of EGFR Mutation and its Subtypes in Lung Adenocarcinoma

By Lu Rong-li   Hu Cheng-Ping   Yang Hua-ping   Li Yuan-yuan   Gu Qi-hua   Wu Lielin  

Pathology & Oncology Research, Vol. 20, Iss. 2, 2014-04 ,pp. : 445-451

Springer Publishing Company

Access to resources Recommend Favorite